Michael M McNeil1, Maria Cano2, Elaine R Miller2, Brett W Petersen3, Renata J M Engler4, Marthe G Bryant-Genevier5. 1. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, United States. Electronic address: mmm2@cdc.gov. 2. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, United States. 3. Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, United States. 4. Vaccine Healthcare Centers Network, Military Vaccine Agency, US Army Public Health Command, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889-5600, United States. 5. Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, United States.
Abstract
BACKGROUND: The Vaccine Adverse Event Reporting System (VAERS) is a passive reporting system, used for monitoring the safety of all US licensed vaccines. In March 2008, ACAM2000(®) replaced Dryvax(®) as the only licensed smallpox vaccine and is administered to all persons entering military service and certain civilian researchers. In 2011, routine data mining of VAERS identified a vaccine safety concern resulting in acute ischemic cardiac events (ICE) following ACAM2000(®). METHODS: During March 1, 2008 through June 30, 2013, we reviewed all serious reports received following ACAM2000(®)and classified them by diagnostic category. We identified possible ICE cases by searching the Medical Dictionary for Regulatory Affairs (MedDRA(®)) terms for "myocardial ischaemia," "acute myocardial infarction," "myocardial infarction," and "ischaemia," and applied standardized surveillance case definitions. RESULTS: VAERS received 1149 reports following ACAM2000(®) administration; 169 (14.7%) were serious (resulting in permanent disability, hospitalization or prolongation of hospitalization, life-threatening illness or death), including one death. The two most frequent diagnostic categories for serious reports were cardiovascular and other infectious conditions. The MedDRA(®) search found 31 reports of possible ICE after receipt of ACAM2000(®) vaccine. Of a total 30 possible ICE cases with demographic information, all but one was male; the age range was 20-45 years (median 32) and median interval to onset of symptoms was 12 days. On clinical review there were 16 cases of myocarditis/pericarditis and 15 ICE cases. CONCLUSIONS: Our review of the data mining signal did not substantiate the concerns about ICE after ACAM2000(®). Our study also suggests that with current pre-vaccination screening, cardiac morbidity in generally healthy vaccinated populations remains uncommon. Published by Elsevier Ltd.
BACKGROUND: The Vaccine Adverse Event Reporting System (VAERS) is a passive reporting system, used for monitoring the safety of all US licensed vaccines. In March 2008, ACAM2000(®) replaced Dryvax(®) as the only licensed smallpox vaccine and is administered to all persons entering military service and certain civilian researchers. In 2011, routine data mining of VAERS identified a vaccine safety concern resulting in acute ischemic cardiac events (ICE) following ACAM2000(®). METHODS: During March 1, 2008 through June 30, 2013, we reviewed all serious reports received following ACAM2000(®)and classified them by diagnostic category. We identified possible ICE cases by searching the Medical Dictionary for Regulatory Affairs (MedDRA(®)) terms for "myocardial ischaemia," "acute myocardial infarction," "myocardial infarction," and "ischaemia," and applied standardized surveillance case definitions. RESULTS: VAERS received 1149 reports following ACAM2000(®) administration; 169 (14.7%) were serious (resulting in permanent disability, hospitalization or prolongation of hospitalization, life-threatening illness or death), including one death. The two most frequent diagnostic categories for serious reports were cardiovascular and other infectious conditions. The MedDRA(®) search found 31 reports of possible ICE after receipt of ACAM2000(®) vaccine. Of a total 30 possible ICE cases with demographic information, all but one was male; the age range was 20-45 years (median 32) and median interval to onset of symptoms was 12 days. On clinical review there were 16 cases of myocarditis/pericarditis and 15 ICE cases. CONCLUSIONS: Our review of the data mining signal did not substantiate the concerns about ICE after ACAM2000(®). Our study also suggests that with current pre-vaccination screening, cardiac morbidity in generally healthy vaccinated populations remains uncommon. Published by Elsevier Ltd.
Authors: Robert E Eckart; Suzanne S Love; J Edwin Atwood; Mark K Arness; Dimitri C Cassimatis; Charles L Campbell; Sheri Y Boyd; Joseph G Murphy; David L Swerdlow; Limone C Collins; James R Riddle; David N Tornberg; John D Grabenstein; Renata J M Engler Journal: J Am Coll Cardiol Date: 2004-07-07 Impact factor: 24.094
Authors: Jens U Rüggeberg; Michael S Gold; José-Maria Bayas; Michael D Blum; Jan Bonhoeffer; Sheila Friedlander; Glacus de Souza Brito; Ulrich Heininger; Babatunde Imoukhuede; Ali Khamesipour; Michel Erlewyn-Lajeunesse; Susana Martin; Mika Mäkelä; Patricia Nell; Vitali Pool; Nick Simpson Journal: Vaccine Date: 2007-03-12 Impact factor: 3.641
Authors: L Sarda; P Colin; F Boccara; D Daou; R Lebtahi; M Faraggi; C Nguyen; A Cohen; M S Slama; P G Steg; D Le Guludec Journal: J Am Coll Cardiol Date: 2001-03-01 Impact factor: 24.094
Authors: John Neff; John Modlin; Guthrie S Birkhead; Gregory Poland; Rose Marie Robertson; Kent Sepkowitz; Clyde Yancy; Pierce Gardner; Gregory C Gray; Toby Maurer; Jane Siegel; Fernando A Guerra; Tim Berger; W Dana Flanders; Robert Shope Journal: Clin Infect Dis Date: 2008-03-15 Impact factor: 9.079
Authors: Jeffrey S Halsell; James R Riddle; J Edwin Atwood; Pierce Gardner; Robert Shope; Gregory A Poland; Gregory C Gray; Stephen Ostroff; Robert E Eckart; Duane R Hospenthal; Roger L Gibson; John D Grabenstein; Mark K Arness; David N Tornberg Journal: JAMA Date: 2003-06-25 Impact factor: 56.272
Authors: Edgar Turner Overton; Steven J Lawrence; Eva Wagner; Katrin Nopora; Siegfried Rösch; Philip Young; Darja Schmidt; Christian Kreusel; Sonja De Carli; Thomas P Meyer; Heinz Weidenthaler; Nathaly Samy; Paul Chaplin Journal: PLoS One Date: 2018-04-13 Impact factor: 3.240
Authors: Andrew T Russo; Douglas W Grosenbach; Jarasvech Chinsangaram; Kady M Honeychurch; Paul G Long; Candace Lovejoy; Biswajit Maiti; Ingrid Meara; Dennis E Hruby Journal: Expert Rev Anti Infect Ther Date: 2020-09-15 Impact factor: 5.854